Quantcast

Latest Exosome Stories

2014-04-22 08:33:24

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b When we initiated our first exosome research program, the medical community generally viewed these particles as nothing more than cellular debris with no biological function. In contrast, we believed that exosomes, also known as microvesicles or extracellular vesicles,...

2014-03-11 08:29:02

NEW YORK, March 11, 2014 /PRNewswire/ -- Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas. Key Points: -- Co-leading the financing were new investors QIAGEN and Arcus Ventures --...

2014-03-05 08:29:37

Discoveries Could Have Implications in the Diagnosis, Monitoring and Treatment of Alzheimer's Disease, Chronic Traumatic Encephalopathy and Traumatic Brain Injury SAN DIEGO, March 5, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications...

2014-02-26 08:29:00

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic...

2014-02-19 23:31:12

Colleen’s Dream Foundation has granted $11,000 to Memorial Sloan-Kettering Cancer Center to help fund ovarian cancer research being conducted by Dr. Vance Broach, according to Colleen’s Dream Foundation President Billy Cundiff. Phoenix, AZ (PRWEB) February 19, 2014 With the help of ovarian cancer survivor Jill Pall and NFL kicker Ryan Quigley, Colleen’s Dream Foundation has granted $11,000, to Memorial Sloan-Kettering Cancer Center to help fund ovarian cancer research being...

2014-01-13 04:20:54

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ -- - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies - Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine - Automated biofluid-based molecular diagnostics have significant potential to...

2014-01-13 04:20:53

-- Collaboration will focus on enabling detection of known cancer biomarkers in blood plasma NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of...

2014-01-09 11:35:24

Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer...

2013-12-13 23:04:48

New England Peptide (NEP), a Massachusetts based biotech manufacturer, and The Atlantic Cancer Research Institute (ACRI), a leading cancer research center in Atlantic Canada, have launched a new biotech company. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both NEP and ACRI for the isolation of exosomes and extracellular microvesicles. Gardner, MA (PRWEB) December 13, 2013 Vn96 is a synthetic peptide that was designed to specifically stick to...

Anthrax Mystery Resolved
2013-11-14 15:12:09

Brett Smith for redOrbit.com - Your Universe Online For years, doctors have wondered why someone with an anthrax infection can die days after the bacteria responsible is wiped out from their body. A new study claims the toxin produced by the bacteria uses a “Trojan horse”-like method to elude the body’s natural defenses. "This remained a mystery for more than 50 years,” said study author Gisou van der Goot, a cell biologist at Switzerland's prestigious École Polytechnique...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.